We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-30.82%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.7B
AUM Growth
-$1.14B
Cap. Flow
+$29.8M
Cap. Flow %
1.1%
Top 10 Hldgs %
59.73%
Holding
123
New
18
Increased
25
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$86.4M
2
BABA icon
Alibaba
BABA
+$51.3M
3
NIO icon
NIO
NIO
+$28.5M
4
ALLO icon
Allogene Therapeutics
ALLO
+$10.6M
5
ARRY
Array Biopharma Inc
ARRY
+$9.1M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$31.2M
2
ANAB icon
AnaptysBio
ANAB
+$11.2M
3
FOLD
Amicus Therapeutics
FOLD
+$11M
4
ZGNX
Zogenix, Inc.
ZGNX
+$8.19M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.69M

Sector Composition

Rank Sector Weight
1 Healthcare 48.78%
2 Consumer Discretionary 24.57%
3 Real Estate 0.28%
4 Communication Services 0.12%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
51
CALL
DELISTED
Acceleron Pharma
XLRN
$8.71M 0.32%
+200,000
New +$9.99M
MDGL icon
52
Madrigal Pharmaceuticals
MDGL
$12.5B
$7.89M 0.29%
70,000
+20,000
+40% +$3.1M
MDCO
53
DELISTED
Medicines Co
MDCO
$7.66M 0.28%
400,000
– –
VICI icon
54
VICI Properties
VICI
$29.8B
$7.51M 0.28%
+400,000
New +$8.41M
ZGNX
55
DELISTED
Zogenix, Inc.
ZGNX
$7.29M 0.27%
200,000
-200,000
-50% -$8.19M
RGNX icon
56
Regenxbio
RGNX
$617M
$7.13M 0.26%
170,000
+20,000
+13% +$1.17M
ACIU icon
57
AC Immune
ACIU
$231M
$7.09M 0.26%
750,000
– –
KYNB
58
CALL
Kyntra Bio
KYNB
$28.1M
$6.94M 0.26%
+6,000
New +$6.74M
VALE icon
59
CALL
Vale
VALE
$62.2B
$6.59M 0.24%
+500,000
New +$7.15M
NKTR icon
60
CALL
Nektar Therapeutics
NKTR
$2.31B
$6.57M 0.24%
13,333
– –
AGEN
61
Agenus
AGEN
$284M
$6.54M 0.24%
140,113
– –
NIO icon
62
CALL
NIO
NIO
$12B
$6.37M 0.24%
+1,000,000
New +$6.96M
CRNX icon
63
Crinetics Pharmaceuticals
CRNX
$8.88B
$6M 0.22%
200,000
– –
RCKT icon
64
Rocket Pharmaceuticals
RCKT
$336M
$5.93M 0.22%
400,000
– –
AXDX
65
DELISTED
Accelerate Diagnostics
AXDX
$5.75M 0.21%
50,000
– –
KRYS icon
66
Krystal Biotech
KRYS
$10.7B
$5.71M 0.21%
275,000
+125,000
+83% +$2.62M
DRNA
67
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.61M 0.21%
525,000
+100,000
+24% +$1.32M
FOLD
68
CALL
DELISTED
Amicus Therapeutics
FOLD
$4.79M 0.18%
500,000
-500,000
-50% -$5.5M
SGMO
69
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.59M 0.17%
400,000
+100,000
+33% +$1.24M
REPL icon
70
Replimune Group
REPL
$431M
$4.5M 0.17%
450,000
– –
TBIO
71
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.5M 0.17%
600,000
– –
IOVA icon
72
Iovance Biotherapeutics
IOVA
$2.07B
$4.42M 0.16%
500,000
-200,000
-29% -$1.93M
CRSP icon
73
CRISPR Therapeutics
CRSP
$4.63B
$4.14M 0.15%
145,000
+45,000
+45% +$1.56M
CBAY
74
DELISTED
Cymabay Therapeutics
CBAY
$3.94M 0.15%
500,000
-300,000
-38% -$2.86M
STML
75
DELISTED
Stemline Therapeutics, Inc.
STML
$3.8M 0.14%
400,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2018 Portfolio in Review

As of Q4 2018, Artal Group held 123 positions worth $2.7B, down 30% from $3.84B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group's Q4 2018 filing shows 18 new, 25 increased, 16 reduced and 19 closed positions. Its largest new stake was Moderna: 5,256,298 shares worth $80.3M. The largest sale was TESARO, Inc., an estimated $31.2M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 46% a quarter earlier, followed by Consumer Discretionary and Real Estate.

  • Artal Group's largest Q4 2018 buy was Moderna: 5,256,298 shares worth $80.3M.
  • Artal Group added most to Alibaba in Q4 2018, an estimated $51.3M increase.
  • Artal Group's biggest Q4 2018 reduction was AnaptysBio, cutting an estimated $11.2M.
  • Artal Group fully exited TESARO, Inc. in Q4 2018, selling an estimated $31.2M.
  • Artal Group's ten largest holdings make up 60% of its $2.7B portfolio in Q4 2018.
  • Artal Group opened 18 new positions and closed 19 in Q4 2018.
  • Artal Group's portfolio value fell 30% quarter-over-quarter to $2.7B.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.